Eye Movements, Visual Perception and Attention

June 3, 2025 updated by: Martina Poletti, University of Rochester
During visual fixation, small eye movements of which we are usually not aware, prevent the maintenance of a steady direction of gaze. These eye movements are finely controlled and shift retinal projection of objects within the fovea, the region of the retina where visual acuity is highest. This program of research examines the link between these eye movements and attention, and tests the hypothesis that attention, similarly to eye movements, can be controlled at the foveal level. Psychophysical experiments with human subjects, using state-of-the-art techniques, high resolution eyetracking and retinal stabilization are conducted to address these questions. Gaze-contingent calibration procedures are employed to achieve high accuracy in gaze localization. A custom developed gaze-contingent display is used to shift in real-time visual stimuli on the monitor to compensate for the observer eye movements during fixation periods and to maintain stimuli at a desired location on the retina. Experiments involve visual discrimination/detection tasks with stimuli presented at selected eccentricities within the fovea. Participants' performance and reaction times are examined under different conditions, in which various types of attention are manipulated. In addition to advancing our basic understanding of visual perception, this research leads to a better understanding of attentional control at the foveal scale and of the contribution of microscopic eye movements to the acquisition and processing of visual details.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The goals of this study are to the following:

  1. Examine the resolution and time-course of attention within the foveola. Attentional control has been traditionally studied outside the foveola but the PI's recent work suggests that attentional shifts also play a critical role in the normal examination of fine spatial details. Building on our previous results, we will investigate the extent by which both voluntary and involuntary attention can be controlled at this scale. Specifically, we will (a) measure the resolution of attention, i.e., the minimum distance between two locations within the foveola that can elicit selective voluntary attentional shifts. We will (b) examine whether enhancements in fine spatial vision at selected foveal locations, such as those we have previously shown for voluntary attention, also occur with involuntary attention. Finally we will study (c) the time-course of attentional enhancements and inhibition of return at this scale. Moreover, to study how peripheral and foveal attention differ, we will compare the extent of exogenous attentional effects and their time-course within and outside the foveola.
  2. Map visual acuity and crowding across the foveola. Our research has shown that vision is not uniform across the foveola: discrimination of fine spatial patterns is already suboptimal just a few arcmins away from the center of gaze. This phenomenon could be caused by a decline in visual acuity outside the preferred retinal locus and/or the consequences of crowding, the negative influence resulting from objects adjacent to the target. Because of the difficulty in precisely controlling retinal stimulation at this scale, it is unclear whether crowding occurs in the foveola, and whether its influence changes with foveal eccentricity. We will measure both visual acuity (a), and crowding (b), and will assess their relative contribution over a range of foveal eccentricities, both nasally and temporally. In addition to examine visual acuity across subjects, we will also examine how it changes at the individual level.
  3. Link attention, fine spatial vision and oculomotor control. Microsaccades normally shift the retinal projection of the fixated object across the foveola. At a larger scale, visual resolution, attention, and eye movements are tightly coupled. But little is known on whether and how this interplay unfolds within the foveola. Here we will investigate how attention and vision interact with microsaccades preparation and execution. We will examine (a) whether microsaccades preparation yields attentional benefits at specific foveal locations; (b) the precision of microsaccades; (c) their impact in attenuating negative effects of reduced acuity and foveal crowding, and; (d) their impact on performance in natural high acuity tasks.

To address these goals psychophysics experimental paradigms and high-precision eyetracking will be used.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
155

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • New York
      • Rochester, New York, United States, 14642
        • University of Rochester

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Subjects will be eligible for the study if they:

    • Are at least 18 years old
    • Speak English
    • Have read, understood, and signed the informed consent form Have normal visual acuity (20/20 or better) without correction (i.e. without glasses or contact lenses) and no known visual deficits. A standard visual acuity screening will be performed by means of a Snellen chart (the standard eye chart) at the beginning and the end of the experiments.

Exclusion Criteria:

  • Subjects will be excluded if they:

    • Are under 18 years old
    • Cannot understand the experimental procedures Have reported vision loss, including the need for correction (i.e. glasses or contact lenses), or fail the visual acuity screening performed during the experiments. We expect a very minor portion of subjects to be excluded as a result of this test, as the good vision requirement will be clearly stated in our recruitment materials. There will be no data collection for subjects who will not pass the acuity test.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Normal Vision
This study examines high-acuity vision, oculomotor behavior recorded using high-resolution eyetracking. Healthy participants are asked to perform different types of visual tasks, ranging from letter identification to judging facial expressions while their eye movements will be recorded with high-precision together with their behavioral performance in the task.
Other: Visual stimulation
In the experiments, participants will sit in front of a computer monitor located a less than a meter of distance and will analyze the content of images extracted from collections of natural and computer-generated scenes. Subjects will be asked to report verbally or by pressing keys on a keyboard on image characteristics such as the locations of the objects present in the scenes, their number and/or their identities. Some experiments will involve a search paradigm in which subjects will have to report on the location and/or fine characteristics of a target element among a field of distracting similar elements, and/or visual discrimination tasks. The duration of the interval of time in which the image is maintained on the screen may be varied between few tens of milliseconds to several seconds. In a set of experiments, the eye movements performed by the subjects during the execution of the visual tasks will be recorded as explained below.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Average Performance in Visual Tasks
Time Frame: Day 0
Proportion correct responses in visual tasks. For each visual stimulus presentation, observers performed a four-alternative forced-choice (4AFC) task. A trial was considered correct if the participant's selected response matched the identity of the presented stimulus; otherwise, it was marked as incorrect.
Day 0
Microsaccades Rate
Time Frame: Day 0
rate of microsaccades per second
Day 0

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Microsaccades rate
Time Frame: Day 0
Average number of microsaccades per second
Day 0

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Rochester

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Eye Institute (NEI)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Martina Poletti, Ph.D., University of Rochester

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2018

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 1, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 1, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 20, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 20, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 21, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 18, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 3, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • RSRB00069578
  • R01EY029788-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings